Report Detail
Purchase Price: $4,750.00
Point-of-Care Diagnostic Products
As access to point-of-care (POC) testing improves and the technology advances, the use of POC testing is becoming more widespread. In 2022, sales of the POC diagnostics covered by this report totaled nearly $27.6bn, with the US accounting for more than half of total sales. Key factors driving growth in the POC diagnostics market include improved access, technological advances, a broadening range of settings for POC diagnostic testing, and an increasing number of available tests for a growing number of target conditions, among other factors. Limiters to market growth include core laboratory validation of POC test results, the high cost of POC testing, and reduced specificity for some POC tests compared to laboratory tests, among other factors. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for POC diagnostic products for infectious disease, cardiovascular disease, cancer, hemostasis, substance abuse, pregnancy/fertility, and other applications (e.g., hemoglobin, urinalysis, lipid, and allergy testing). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2022–27.
If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].
Related Medtech Insight articles:
